Tarlatamab: First Approval

2024/07/18 by Sohita Dhillon · 29 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Research Studies #Cancer therapeutics and mechanisms #Lung Cancer Treatments and Mutations

paper · doi:10.1007/s40265-024-02070-z

Cited by

• Delta-like Ligand 3Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models
• Trendbericht: Organische Chemie 2025
• Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy
• Structure and function of therapeutic antibodies approved by the US FDA in 2024
• Relationship between the expressions of DLL3, ASC1, TTF-1 and Ki-67: First steps of precision medicine at SCLC. [europepmc]
• A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024. [europepmc]
• Emerging Strategies of Cell and Gene Therapy Targeting Tumor Immune Microenvironment. [europepmc]
• Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer. [europepmc]
• Unravelling T cell exhaustion through co-inhibitory receptors and its transformative role in cancer immunotherapy. [europepmc]
• Engaging T cells for cleanup. [europepmc]
• Immunomodulation and Immunotherapy for Patients with Prostate Cancer: An Up-to-Date Review. [europepmc]
• Harnessing delta-like ligand 3: bridging biomarker discovery to next-generation immunotherapies in refractory small cell lung cancer. [europepmc]
• Bispecific Antibodies in Solid Tumors: Advances and Challenges. [europepmc]
• MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game. [europepmc]
• Reprogramming cancer immunity with next-generation combination therapies. [europepmc]
• Structure and function of therapeutic antibodies approved by the US FDA in 2024. [europepmc]
• Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. [europepmc]
• Immunotherapy for small cell lung cancer: current challenges and prospects. [europepmc]
• New Treatment Options for Pancreatic Neuroendocrine Tumors: A Narrative Review. [europepmc]
• Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics. [europepmc]
• Molecular features of response and resistance to glofitamab, a T-cell engager for treatment of large B-cell lymphoma. [europepmc]
• Leveraging T cells for cancer immunotherapy. [europepmc]
• Delta-like Ligand 3-Directed 225 Ac Radioimmunotherapy in Neuroendocrine Lung and Prostate Cancer Models. [europepmc]
• Delta-like ligand 3 expression in isocitrate dehydrogenase-mutant and isocitrate dehydrogenase-wildtype glioma is largely retained at recurrence, supporting its potential as a therapeutic target. [europepmc]
• A Roadmap to Transform Lung Cancer Outcomes: Priorities in Biology, Therapeutic Innovation, Early Detection, Prevention, and Interception. [europepmc]
• Immune cell engagers in lung cancer. [europepmc]
• Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors. [europepmc]
• Docetaxel enhances Vβ-directed T-cell activation and antitumor immunity mediated by a bifunctional TCR agonist in breast and prostate cancer models. [europepmc]
• Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events. [europepmc]